Disclosed is the use of rimonabant for the manufacture of a medicament for the treatment or prevention of a disease related to dyslipidemia and/or obesity, wherein the disease is metabolic syndrome or liver steatosis, in which the medicament further comprises an angiotensin II AT1 receptor antagonist. Further disclosed is a medicament comprising rimonabant and an angiotensin II AT1 receptor antagonist, and optionally a diuretic or a calcium antagonist.

Use of cannabinoid receptor antagonists (I), preferably rimonabant or N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole -3-carboxamide, for the preparation of drugs in the treatment and prevention of type-2 diabetes. An independent claim is included for a pharmaceutical composition comprising cannabinoid receptor antagonists and active ingredients. - ACTIVITY : Antidiabetic. - MECHANISM OF ACTION : Cannabinoid receptor antagonists.

The invention concerns a novel crystalline polymorph of rimonabant its preparation method and pharmaceutical compositions containing said novel polymorph.

A crystalline polymorph of rimonabant (form II) is disclosed. A method for preparing a crystalline polymorph of rimonabant (form II), comprising: a) rimonabant is dissolved in the hot state in a solvent chosen from: -methylcyclohexane in the pure state or containing 1 to 10% of water by volume, -acetonitrile -4-methyl-2-pentanone -acetone, or a mixture of these solvents